Hubei Biocause Pharmaceutical Co., Ltd. operates in the Life insurance sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hubei Biocause Pharmaceutical Co., Ltd. with three other
insurance companies in Asia:
Sbi Life Insurance Company Ltd
of INDIA
(2019
sales of 446.68 billion Indian Rupees [US$6.05 billion]
of which 49%
was Segment J - Linked Individual Life),
Mercuries Life Insurance Co Ltd
of TAIWAN
(183.01 billion Taiwanese Dollars [US$6.43 billion]
of which 43%
was Personal Life Insurance Product), and
Mercuries & Associates Holding Ltd
which is
also
based in TAIWAN
(209.68 billion Taiwanese Dollars [US$7.36 billion]
of which 86%
was Life Insurance).
Sales Analysis.
Hubei Biocause Pharmaceutical Co., Ltd. reported sales of 50.19 billion Chinese Renmimbi (US$7.63 billion)
for the
year ending
December of 2019.
This
represents
an
increase of 64.7%
versus 2018, when the company's sales were 30.47 billion Chinese Renmimbi.
Despite this increase, sales are still
below the level achieved in 2017, when Hubei Biocause Pharmaceutical Co., Ltd.
reported sales of 53.41 billion Chinese Renmimbi.